# ANVS (Annovis Bio, Inc.) - SEC EDGAR Financial Statements

> Annovis Bio, Inc. reported $0 in revenue and a net loss of $51.72M for the trailing twelve months ended September 30, 2026.

- Canonical: https://convexityos.com/fundamentals/ANVS
- Markdown: https://convexityos.com/fundamentals/ANVS.md
- SEC CIK: 0001477845
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:01 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001477845&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $0 | Sep 30, 2026 |
| Operating Income | TTM | -$59.07M | Operating profit |
| Net Income | TTM | -$51.72M | GAAP bottom line |
| Diluted EPS | TTM | -$1.21 | Split-adjusted |
| Free Cash Flow | TTM | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $2.82M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 | $0 | $0 | -- |
| Research & Development | $25.22M | $20.00M | $38.79M | $16.52M | $8.48M | $3.05M | $776K |
| Total Operating Expenses | $29.70M | $26.69M | $45.04M | $25.51M | $14.54M | $6.64M | $1.61M |
| **Operating Income** | -$29.70M | -$26.69M | -$45.04M | -$25.51M | -$14.54M | -$6.64M | -$1.61M |
| Interest Income | $699K | $332K | $668K | -- | -- | -- | -- |
| Income Before Tax | -- | -- | -$56.20M | -$25.33M | -$14.49M | -$5.46M | -$991K |
| Income Tax Expense | $0 | -- | -- | -- | -- | -- | -- |
| **Net Income** | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -$14.49M | -$5.46M | -$991K |
| Basic EPS | -$1.40 | -$2.02 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | -$3.51 |
| **Diluted EPS** | -$1.40 | -$2.31 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | -$3.51 |
| Basic Shares Outstanding | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M | 282.6K |
| Diluted Shares Outstanding | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M | 282.6K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & Development | $15.78M | $12.01M | $16.72M | $8.75M | $6.29M | $5.16M | $5.01M | $5.00M |
| Total Operating Expenses | $16.97M | $14.38M | $18.01M | $9.71M | $7.43M | $6.27M | $6.28M | $6.73M |
| **Operating Income** | -$16.97M | -$14.38M | -$18.01M | -$9.71M | -$7.43M | -$6.27M | -$6.28M | -$6.73M |
| Interest Income | $85K | $160K | $138K | $168K | $152K | $191K | $188K | $126K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -- |
| **Net Income** | -$9.46M | -$14.82M | -$17.61M | -$9.83M | -$7.26M | -$6.22M | -$5.54M | -$5.86M |
| Basic EPS | -$0.22 | -$0.40 | -$0.63 | -- | -$0.37 | -$0.32 | -$0.32 | -- |
| **Diluted EPS** | -$0.22 | -$0.40 | -$0.63 | -- | -$0.37 | -$0.32 | -$0.32 | -- |
| Basic Shares Outstanding | 42.6M | 37.5M | 27.8M | -- | 19.7M | 19.5M | 17.4M | -- |
| Diluted Shares Outstanding | 42.6M | 37.5M | 27.8M | -- | 19.7M | 19.5M | 17.4M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 | FY 2022 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $19.53M | $10.55M | $5.75M | $28.38M | $31.99M | $35.97M | $42.67M | $45.69M | $8.07M | $1.9K |
| **Cash & Short-Term Investments** | $19.53M | $10.55M | $5.75M | $28.38M | $31.99M | $35.97M | $42.67M | $45.69M | $8.07M | $1.9K |
| **Total Current Assets** | -- | -- | $10.21M | $36.02M | $37.12M | $39.97M | $44.10M | $46.00M | $8.12M | $748K |
| **Total Non-Current Assets** | -- | -- | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $370K |
| **Total Assets** | $21.08M | $13.93M | $10.21M | $36.02M | $37.12M | $39.97M | $44.10M | $46.00M | $8.12M | $1.12M |
| Accounts Payable | $2.59M | $2.31M | $1.29M | $3.96M | $1.85M | $902K | $929K | $688K | $342K | $1.23M |
| **Total Current Liabilities** | $3.64M | $3.88M | $4.28M | $7.70M | $2.53M | $1.30M | $1.40M | $1.51M | $578K | $2.01M |
| **Total Non-Current Liabilities** | $595K | $737K | $13.68M | $0 | $0 | $0 | $0 | $0 | $0 | $606K |
| **Total Liabilities** | $4.23M | $4.62M | $17.96M | $7.70M | $2.53M | $1.30M | $1.40M | $1.51M | $578K | $2.62M |
| Common Stock | $2.7K | $1.4K | $1.1K | $816 | $816 | $816 | $816 | $810 | $689 | $28 |
| Retained Earnings | -$163.7M | -$134.8M | -$110.3M | -$54.05M | -$46.33M | -$39.90M | -$33.96M | -$28.73M | -$14.24M | -$8.78M |
| **Total Stockholders' Equity** | $16.85M | $9.31M | -$7.75M | $28.32M | $34.59M | $38.67M | $42.70M | $44.49M | $7.54M | -$8.58M |
| Total Equity | $16.85M | $9.31M | -$7.75M | $28.32M | $34.59M | $38.67M | $42.70M | $44.49M | $7.54M | -$8.58M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $2.82M | $18.73M | $14.22M | $19.53M | $15.29M | $17.13M | $22.24M | $10.55M |
| **Cash & Short-Term Investments** | $2.82M | $18.73M | $14.22M | $19.53M | $15.29M | $17.13M | $22.24M | $10.55M |
| **Total Assets** | $5.50M | $22.04M | $16.24M | $21.08M | $17.19M | $21.45M | $26.74M | $13.93M |
| Accounts Payable | $3.05M | $3.33M | $5.28M | $2.59M | $2.11M | $974K | $1.37M | $2.31M |
| **Total Current Liabilities** | $6.26M | $6.36M | $12.79M | $3.64M | $3.73M | $2.81M | $2.50M | $3.88M |
| **Total Non-Current Liabilities** | $12.47M | $19.93M | $327K | $595K | $299K | $319K | $179K | $737K |
| **Total Liabilities** | $18.74M | $26.29M | $13.12M | $4.23M | $4.03M | $3.12M | $2.68M | $4.62M |
| Common Stock | $4.3K | $4.3K | $2.9K | $2.7K | $2.0K | $1.9K | $1.9K | $1.4K |
| Retained Earnings | -$205.6M | -$196.1M | -$181.3M | -$163.7M | -$153.9M | -$146.6M | -$140.4M | -$134.8M |
| **Total Stockholders' Equity** | -$13.23M | -$4.25M | $3.13M | $16.85M | $13.16M | $18.33M | $24.05M | $9.31M |
| Total Equity | -$13.23M | -$4.25M | $3.13M | $16.85M | $13.16M | $18.33M | $24.05M | $9.31M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -$14.49M | -$5.46M | -$991K |
| Stock-Based Compensation | $1.80M | $3.84M | $4.63M | $9.15M | $4.70M | $1.86M | $8.5K |
| Change in Payables | $285K | $1.01M | -$2.67M | $3.27M | $346K | -$696K | $969K |
| **Operating Cash Flow** | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -$9.13M | -$3.97M | -$477K |
| Common Stock Issued | -- | $18.67M | $16.89M | -- | $46.65M | $12.03M | -- |
| **Financing Cash Flow** | $34.60M | $26.69M | $17.34M | $4.6K | $46.74M | $12.04M | $443K |
| **Net Change in Cash** | $8.98M | $4.80M | -$22.62M | -$17.31M | $37.61M | $8.07M | -$33K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$9.46M | -$14.82M | -$17.61M | -$9.83M | -$7.26M | -$6.22M | -$5.54M | -$5.86M |
| Stock-Based Compensation | $355K | $1.61M | $183K | $357K | $445K | $497K | $500K | $1.48M |
| Change in Payables | -$274K | -$1.95M | $2.69M | $478K | $1.14M | -$396K | -$936K | -$1.79M |
| **Operating Cash Flow** | -$16.04M | -$21.91M | -$9.01M | -$8.93M | -$3.49M | -$5.11M | -$8.10M | -$8.29M |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | -- | $6.20M |
| **Financing Cash Flow** | $128K | $26.42M | $3.70M | $13.17M | $1.64M | $0 | $19.78M | $6.20M |
| **Net Change in Cash** | -$15.91M | $4.51M | -$5.31M | $4.25M | -$1.84M | -$5.11M | $11.68M | -$2.08M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -171.2% | -264.2% | -- | -89.4% | -32.6% | -72.4% | -- |
| Return on Assets (ROA) | -136.9% | -176.6% | -550.6% | -70.3% | -31.5% | -67.3% | -88.7% |
| Current Ratio | -- | -- | 2.39x | 4.68x | 30.54x | 14.04x | 0.37x |
| Quick Ratio | 5.37x | 2.72x | 1.34x | 3.69x | 30.33x | 13.96x | 0.00x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -1309.1% | -171.2% | -189.1% | -165.1% | -120.8% | -264.2% |
| Return on Assets (ROA) | -939.8% | -224.7% | -251.9% | -136.9% | -144.8% | -141.0% | -108.7% | -176.6% |
| Quick Ratio | 0.45x | 2.95x | 1.11x | 5.37x | 4.09x | 6.11x | 8.88x | 2.72x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
